冠心静胶囊治疗冠心病心绞痛的临床疗效及经济学评价

发布时间：2018-03-29 15:11

本文选题：冠心病心绞痛　切入点：冠心静胶囊　出处：《中国药物评价》2017年01期

【摘要】：目的:评价冠心静胶囊治疗冠心病心绞痛的临床疗效和经济性,为临床治疗提供参考依据。方法:采用前瞻性随机对照、双盲、多中心临床试验。根据冠心静胶囊销售地区和医院分布情况选择国内11家医院420例患者作为研究对象,其中冠心静胶囊组313例、参芍胶囊组107例,治疗4周。以心绞痛症状疗效、中医症候疗效、硝酸甘油减停率、心电图有效率、Duck评分改善和运动持续时间改善为疗效指标,经济性分析方法采用成本效果分析,以药品的价格为变量进行单因素敏感性分析。结果:试验组的心绞痛症状疗效、中医证候疗效优于对照组。硝酸甘油减停率、心电图有效率、Duck评分改善和运动持续时间改善两组疗效相当。成本效果分析结果显示,冠心静胶囊更具有经济性,敏感性分析结果不改变基础分析结果。结论:冠心静胶囊治疗冠心病心绞痛的疗效确切,临床用药安全,其经济性优于参芍胶囊。
[Abstract]:Objective: to evaluate the clinical efficacy and economy of Guanxinjing capsule in the treatment of angina pectoris of coronary heart disease, and to provide reference for clinical treatment. According to the distribution of Guanxinjing capsule in local and hospital, 420 patients in 11 hospitals in China were selected as the study objects, including 313 cases in Guanxinjing capsule group and 107 cases in Shenshao capsule group. For 4 weeks, the therapeutic effect of angina pectoris, TCM symptom, nitroglycerin reduction and stopping rate, the improvement of electrocardiogram effective rate and the improvement of exercise duration were taken as the therapeutic indexes, and the cost effect analysis was used in the economic analysis method. Single factor sensitivity analysis was carried out with the price of drugs as variable. Results: the effect of angina pectoris symptom and TCM syndrome in the trial group was better than that in the control group. The results of cost-effect analysis showed that Guanxinjing capsule was more economical. Conclusion: Guanxinjing capsule is effective and safe in the treatment of angina pectoris of coronary heart disease, and its economy is superior to Shenshao capsule.
【作者单位】：中国中药协会中药药物经济学专业委员会;北京康派特医药科技开发有限公司;
【分类号】：R259

【参考文献】